DARE Dare Bioscience Inc

Price (delayed)

$2.21

Market cap

$33.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$16.2M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse ...

Highlights
The debt has dropped by 55% year-on-year and by 39% since the previous quarter
DARE's EPS is up by 20% since the previous quarter
The equity has soared by 108% YoY but it has plunged by 74% from the previous quarter
The company's quick ratio has surged by 86% YoY but it fell by 15% QoQ
The company's gross margin has shrunk by 59% YoY and by 25% QoQ
The company's gross profit fell by 16% QoQ

Key stats

What are the main financial stats of DARE

DARE stock price

How has the Dare Bioscience stock price performed over time
Intraday
7.8%
1 week
-3.07%
1 month
-28.94%
1 year
-28.71%
YTD
14.51%
QTD
21.43%

Financial performance

How have Dare Bioscience's revenue and profit performed over time
Revenue
$1.16M
Gross profit
$619,097
Operating income
-$11.97M
Net income
-$12.02M
Gross margin
53.5%
Net margin
-1,038.8%
The operating margin has soared by 99% YoY and by 21% from the previous quarter
The net margin has soared by 84% year-on-year and by 20% since the previous quarter
The company's gross margin has shrunk by 59% YoY and by 25% QoQ
The company's operating income rose by 46% YoY and by 12% QoQ

Price vs fundamentals

How does DARE's price correlate with its fundamentals

Growth

What is Dare Bioscience's growth rate over time

Valuation

What is Dare Bioscience stock price valuation
P/E
N/A
P/B
43.81
P/S
27.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14
DARE's EPS is up by 20% since the previous quarter
The equity has soared by 108% YoY but it has plunged by 74% from the previous quarter
DARE's revenue is up by 12% QoQ

Efficiency

How efficient is Dare Bioscience business performance
DARE's return on sales has surged by 84% year-on-year and by 20% since the previous quarter
The ROA has grown by 18% from the previous quarter

Dividends

What is DARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DARE.

Financial health

How did Dare Bioscience financials performed over time
The total assets is 2.7% more than the total liabilities
The company's quick ratio has surged by 86% YoY but it fell by 15% QoQ
The current ratio has soared by 84% YoY but it has contracted by 10% from the previous quarter
The debt is 120% greater than the equity
The debt to equity has soared by 137% from the previous quarter
The equity has soared by 108% YoY but it has plunged by 74% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.